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Abstract: This paper summarizes the current epidemiological evidence on coffee 
consumption in relation to blood pressure (BP) and risk of hypertension. Data from cross-
sectional studies suggest an inverse linear or U-shaped association of habitual coffee use with 
BP in different populations. Prospective studies suggest a protective effect of high coffee 
intake (4 or more cups per day) against hypertension, mainly in women. Furthermore, the risk 
of hypertension may be lower in coffee abstainers. Randomized controlled trials, which are 
mostly of short duration (1–12 weeks), have shown that coffee intake around 5 cups per day 
causes a small elevation in BP (∼2/1 mmHg) when compared to abstinence or use of decaf-
feinated coffee. With regard to underlying biological mechanisms, most research has been 
devoted to BP-raising effects of caffeine. However, there are many other substances in coffee, 
such as polyphenols, soluble ﬁ  bre and potassium, which could exert a beneﬁ  cial effect in the 
cardiovascular system. Although the precise nature of the relation between coffee and BP is 
still unclear, most evidence suggests that regular intake of caffeinated coffee does not increase 
the risk of hypertension.
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Introduction
Hypertension is an important risk factor for the development of stroke, coronary heart 
disease, and congestive heart failure (MacMahon et al 1990; Stamler et al 1993). The 
estimated total number of adults with hypertension in 2000 was 972 million, and this 
may increase by about 60% to a total of 1.56 billion in 2025 (Kearney et al 2005). 
A prolonged reduction of diastolic blood pressure (BP) of only 5 mmHg in the general 
population may reduce the number of strokes by 34% and the number of myocardial 
infarctions by 21% (MacMahon et al 1990; Stamler et al 1993). Many dietary and 
lifestyle factors have been implicated in the etiology of hypertension (Beilin et al 
1999), of which overweight, physical inactivity, excessive salt consumption, and low 
potassium intake are the most important contributors in Western societies (Geleijnse 
et al 2004). The epidemiological evidence for an effect of coffee on BP is summarized 
in this review, with a focus on habitual (‘chronic’) intake because of its relevance to 
public health. Short-term, acute effects of coffee intake or caffeine administration on 
BP have been addressed by others (Nurminen et al 1999), and are beyond the scope of 
this review. Before discussing scientiﬁ  c evidence on the relation between coffee and 
BP, the state of the art on coffee intake in relation to cardiovascular disease is brieﬂ  y 
discussed, and an overview of different epidemiological study designs is given with 
their strengths and limitations. Subsequently, cross-sectional and prospective cohort 
data on coffee and BP are summarized, followed by a discussion of experimental 
evidence from randomized controlled trials (RCTs). Finally, potential biological 
pathways for an effect of coffee on BP are brieﬂ  y described, which is followed by an 
overall discussion of the total available evidence. Coffee in this review is considered 
to be ﬁ  ltered caffeinated coffee, except when stated otherwise.Vascular Health and Risk Management 2008:4(5) 964
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Coffee and cardiovascular disease
Several large cohort studies reported no association between 
habitual coffee intake and risk of CVD (Grobbee et al 1990; 
Willett et al 1996; Woodward and Tunstall-Pedoe 1999; 
Andersen et al 2006; Lopez-Garcia et al 2006). Coffee 
neither inﬂ  uenced prognosis after myocardial infarction 
(Mukamal et al 2004). Soﬁ   and colleagues (2006) performed 
a meta-analysis of 23 epidemiological studies on coffee, that 
included in total 403,631 participants. Despite a signiﬁ  cant 
association between high daily coffee intake and coronary 
heart disease in case-control studies, no signiﬁ  cant relation 
emerged from long-term follow-up prospective cohort 
studies (Soﬁ   et al 2006). Among the studies that suggested 
an inverse relation of coffee with CVD are the Iowa 
Women’s Health Study in over 41,000 women aged 55–69 
(Andersen et al 2006), and the Scottish Heart Health Study 
in over 11,000 men and women aged 40–59 (Woodward 
and Tunstall-Pedoe 1999). Coffee may also protect against 
diabetes mellitus type 2. In a Dutch epidemiological 
study among over 17,000 men and women, subjects who 
drank 7 or more cups of coffee per day had only half the 
risk of developing diabetes compared to subjects who drank 
2 cups or less (Van Dam and Feskens 2002). Van Dam and 
Hu (2005) conducted a meta-analysis of 15 epidemiological 
studies in which they showed that the risk of type 2 diabetes 
was 35% lower in subjects who drank over 6 or 7 cups 
of coffee per day, and 28% lower in subjects who drank 
4–6 cups per day, compared to subjects with zero or low 
intake (∼2 cups per day). The underlying mechanisms for a 
potentially protective effect of coffee on CVD and diabetes, 
including the possible role of BP, remain to be elucidated.
Methodological aspects 
of epidemiological studies
Observational (cohort) studies, mainly cross-sectional studies, 
have the major advantage that they can provide insight into 
the long-term effects of coffee on BP. Furthermore, the 
large sample size allows examination of different doses of 
coffee and possible effect modiﬁ  cation by gender, age, race, 
cardiovascular risk proﬁ  le, and other characteristics. It should 
be noted, however, that observational evidence can never be 
used to demonstrate causality. Coffee drinking is part of an 
individual’s lifestyle (Schwarz et al 1994) and is related to 
many other factors, such as alcohol intake, mental stress, and 
dietary habits, which may also inﬂ  uence BP. Therefore, 
when interpreting observational data, one should make 
certain that potential confounders have been adequately 
adjusted for. Residual confounding in the data, eg, by lack 
of adjustment for physical activity, may distort the 
relation between coffee consumption and BP. Cohort 
studies often include many subjects. However, a large 
sample size is by no means a guarantee for the internal 
validity of a study and may even hamper the accurate 
measurement of dietary and lifestyle factors (leading to 
residual confounding). Inaccurate measurement of cof-
fee intake further leads to misclassiﬁ  cation of subjects, 
which could yield a diluted (attenuated) estimate for 
the coffee-BP association. Cross-sectional studies or 
surveys, in which coffee intake and BP are measured at 
the same point in time, have the additional problem of 
‘reverse causation’. Since there is no time span between 
the assessment of coffee intake and BP measurement, it 
is possible that people who are aware of having high BP 
have already adapted their level of coffee consumption. 
As a result, a biased relation may be found between low 
(in fact: lowered) coffee intake and high BP levels.
A main feature of experimental studies, or RCTs, is 
that both the intervention (eg, use of coffee or caffeine 
tablets) and control treatment (eg, decaffeinated coffee or 
placebo) are randomly assigned to participating subjects. By 
this means, any confounders that could distort the relation 
between coffee and BP are equally distributed over both 
groups, and a valid estimate of the effect of coffee on BP 
can be obtained. RCTs are therefore considered the ‘gold 
standard’ in epidemiological research, and may even provide 
insight into causal effects when conducted in a double-blind 
manner. However, compared to observational epidemio-
logical studies, they have the disadvantage that only ﬁ  xed 
doses of coffee or caffeine can be studied during a relatively 
short period of time. Furthermore, trials may suffer from 
poor adherence to the assigned treatments, unsuccessful 
randomization (in small trials), or lack of blinding of the 
participant and/or investigator, which could introduce bias. 
Also, the number of subjects that can participate in a RCT 
is limited.
Coffee and BP: evidence
from observational studies
Cross-sectional studies
Cross-sectional studies of coffee intake and BP date from the 
early 1980s. Lang and colleagues (1983a) performed a cross-
sectional analysis of coffee and BP in 6,321 adults from Paris. 
After controlling for age, sex, BMI, alcohol consumption, 
smoking and socioeconomic status, systolic BP appeared to 
be higher in coffee drinkers (Lang et al 1983a). In a similar 
analysis by this group among 1,491 subjects from Algiers, Vascular Health and Risk Management 2008:4(5) 965
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diastolic BP was elevated in coffee drinkers after adjustment 
for sex, age, BMI, physical activity, rural versus urban resi-
dency, smoking, and tea consumption (Lang et al 1983b). 
BP differences in both studies were modest (2–3 mmHg). 
A small study in 255 Dutch elderly showed a positive rela-
tion of coffee use with BP, but only in women (Löwik et al 
1991). Burke and colleagues (1992) also showed a positive 
relation in 843 Australian men and women aged 60–87, but 
only in coffee drinkers who used antihypertensive drugs. 
Narkiewicz and colleagues (1995) found higher systolic BP 
in Italian men who took 4 or more cups of coffee per day 
compared to nondrinkers, but only for daytime ambulatory 
BP and not for ofﬁ  ce BP.
In 5,147 Australian adults, caffeine consumption (mainly 
through coffee) within the last 3 hours was associated with 
higher BP in both sexes after controlling for age, adiposity, 
family history of hypertension, serum cholesterol, alcohol 
use, and smoking (Shirlow et al 1988). Average daily 
caffeine intake, on the other hand, was not associated 
with BP in this survey. Similarly, in a Swiss study in 
338 young women, coffee consumption on the testing day 
was related to elevated BP whereas no association was 
found with habitual coffee intake (Höfer and Bättig 1993). 
In the CARDIA study of 5,115 black and white young adults 
(Lewis et al 1993), caffeine intake (up to 800 mg/d) through 
foods and beverages was not consistently related to BP 
when controlling for age, sex, race, physical activity, BMI, 
oral contraceptive use, alcohol use, smoking, and other 
potential confounders. An analysis of Framingham data 
that comprised over 6,000 middle-aged men and women 
neither showed a signiﬁ  cant relation of coffee intake with 
BP (Wilson et al 1989).
Two large US cross-sectional studies showed a nega-
tive (inverse) correlation of coffee with BP (Prineas et al 
1980; Klatsky et al 1986). This was conﬁ  rmed in a survey 
of 500 Italian health care workers (Periti et al 1987), 
where BP declined by 0.8/0.5 mmHg per cup. Another 
Italian study by Salvaggio and colleagues (1990) among 
9,601 adults showed 2–3 mmHg lower systolic BP in 
subjects who drank 4–5 cups of coffee per day compared 
to abstainers. Similarly, in 336 male self-defense ofﬁ  cials 
in Japan, daily coffee drinking was associated with lower 
BP (around 0.5 mmHg/cup), after adjustment for green tea 
intake, alcohol use, smoking, body mass index (BMI), and 
diabetes (Wakabayashi et al 1998). In another Japanese 
study of 1,902 men and women aged 40+ from Tanushi-
maru, one of the cohorts of the Seven Countries Study, 
coffee consumption was inversely related to BP whereas 
intake of green tea was not (Hino et al 2007). Coffee was 
also weakly inversely correlated with systolic and diastolic 
BP in the Danish MONICA cohort after multivariable 
adjustment (Kirchoff et al 1994). In the Copenhagen Male 
Study of 2,975 older men, BP levels and prevalence of 
hypertension declined across coffee categories after multi-
variable adjustment, ie, 123/74 mmHg (14% hypertensive) 
for 1–4 cups, 121/72 mmHg (11%) for 5–8 cups, and 
117/70 mmHg (7%) for 9+ cups per day (Gyntelberg 
et al 1995). BP data in abstainers were not presented in 
this study. A UK health check in 1989–1993 showed 
that habitual coffee intake (mainly instant) was inversely 
related to systolic BP in 478 men, with levels gradually 
declining from 134 mmHg in abstainers to 126 mmHg in 
subjects drinking more than 6 cups per day (Lancaster et al 
1994). In 586 UK women an inverse U-shaped relation was 
seen, with highest systolic BP levels for 1–2 cups per day 
(128 mmHg) and lowest levels for >6 cups per day 
(117 mmHg). Data were adjusted for age, BMI, smoking, 
alcohol use, and physical activity (Lancaster et al 1994). 
A Norwegian study of almost 30,000 middle-aged men and 
women also showed an inverse U-shaped relation, with 
lowest BP values both in abstainers and in coffee drinkers 
who took 9 or more cups per day (Stensvold et al 1989). 
Lopez-Garcia and colleagues (2006) in a cross-sectional 
analysis of 730 healthy and 663 diabetic women from 
the Nurses’ Health Study I cohort, studied caffeinated 
and decaffeinated coffee in relation to endothelial func-
tion and found no association. In these data, an inverse 
U-shaped relation between coffee intake and presence of 
hypertension was seen in healthy women, with a larger 
proportion of hypertensives for intakes around 1 cup per 
day (25%) compared to 1 cup per month (8%) and 2+ cups 
per day (17%). However, these data were not adjusted for 
confounders although mean age was similar across coffee 
categories (Lopez-Garcia et al 2006).
Summarizing, data from cross-sectional studies provide 
little support for a BP-raising effect of coffee, with the pos-
sible exception for BP measured shortly after coffee intake. 
Rather, the data suggest an inverse linear or U-shaped 
relation of habitual coffee intake with BP in populations 
from Europe, Asia and USA (Prineas and Jacobs 1980; 
Klatsky et al 1986; Periti et al 1987; Stensvold et al 1989; 
Salvaggio et al 1990; Kirchoff et al 1994; Lancaster et al 
1994; Gyntelberg et al 1995; Wakabayashi et al 1998; 
Lopez-Garcia et al 2006; Hino et al 2007), although this 
inverse relation may be absent at young age as shown in 
the CARDIA study (Lewis et al 1993). Gender does not Vascular Health and Risk Management 2008:4(5) 966
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seem to inﬂ  uence the relation of coffee with BP on basis 
of cross-sectional evidence.
Prospective studies
Only few prospective (ie, longitudinal or follow-up) studies of 
coffee and (change in) BP or incidence of hypertension have 
been performed. In an Australian cohort of working men, 
coffee consumption was associated with elevated BP during 
6 years of follow-up (Jenner et al 1988). In a prospective 
study in 1,017 male medical alumni with 33 years of follow-
up, coffee intake was positively associated with self-reported 
systolic BP (0.19 mmHg) and diastolic BP (0.27 mmHg) per 
cup per day, after adjustment for parental hypertension, BMI, 
smoking, alcohol use, and physical activity (Klag et al 2002). 
Compared with abstainers, coffee drinkers were at higher 
risk of developing hypertension, with the risk maximally 
increased by 49% for baseline intakes of 3–4 cups/day, but 
ﬁ  ndings were no longer statistically signiﬁ  cant after multi-
variable adjustment (Klag et al 2002).
In a large study of habitual caffeine intake and risk of 
hypertension, Winkelmayer and colleagues (2005) analyzed 
data from a large prospective cohort study in 155,594 US 
nurses. Intake of caffeinated coffee was weakly inversely 
related to incident hypertension, with around 10% reduction 
in risk in women who drank 4 or more cups compared to 
women drinking 3 or less cups per day. Data were adjusted for 
age, BMI, family history of hypertension, physical activity, 
smoking, oral contraceptive use (in female subjects), and 
intake of alcohol, tea, and cola. Interestingly, contrary to 
coffee, an high intake of cola signiﬁ  cantly increased the risk 
of hypertension in these women (Winkelmayer et al 2005).
Recently, a prospective analysis of coffee intake and 
incident hypertension has been performed in 2,985 men 
and 3,383 women in The Netherlands with over 10 years 
of follow-up (Uiterwaal et al 2007). This study showed an 
inverse U-shaped relation in women, with abstainers having a 
49% reduced risk and women who drank more than 6 cups per 
day having a 33% reduced risk of hypertension compared to 
light coffee drinkers (0–3 cups per day). Data were adjusted 
for age, height and weight, smoking, socioeconomic status, 
and intake of tea, alcohol, and total energy. In men, the risk 
of hypertension also tended to be reduced in abstainers but 
data were not statistically signiﬁ  cant (Uiterwaal et al 2007). 
Overall, the inverse association between coffee and hyperten-
sion was mainly present in older subjects (39 years). On 
the other hand, an Italian study in 800 men and 307 women 
with elevated BP (mean age: 33 years) showed that coffee 
drinkers developed sustained hypertension more frequently 
than abstainers (53% vs 44%) during more than 6 years of 
follow-up (Hu et al 2007). The Italian ‘espresso’ coffee 
was the predominant type of coffee in this study, which is 
prepared without a paper ﬁ  lter. In 2,505 Finnish subjects aged 
25–64 with 13 years of follow-up, the risk of initiating antihy-
pertensive treatment was increased by 20%–30% in subjects 
who drank 2–7 cups daily, compared to those who drank 
0–1 cups (Palatini et al 2007). Around 12% of this Finnish 
cohort drank unﬁ  ltered pot-boiled coffee. Interestingly in this 
study, the risk in subjects who drank 8 or more cups per day 
was only increased by 14%, and adjustment for baseline BP 
attenuated the associations (Palatini et al 2007).
In conclusion, prospective epidemiological studies do 
not provide a clear picture on the role of coffee intake in 
the development of hypertension. Risks may be lower both 
in abstainers and in subjects with a relatively high intake, 
although this was not found in all studies. Especially in 
female coffee drinkers, the risk of hypertension may be 
reduced at higher intakes (4–6 cups/day). The number of 
studies, however, is small, which hampers the drawing of 
conclusions.
Coffee and BP: evidence from RCTs
A large number of RCT of either coffee or caffeine intake 
on BP have been performed, which have been systemati-
cally reviewed by different research groups (Myers 1988; 
Jee et al 1999; Nurminen et al 1999; Noordzij et al 2005). 
Myers (1988) provided an overview of BP trials with daily 
caffeine doses around 100–500 mg that were published 
between 1978–1987 and found that caffeine did not cause 
any persistent increase in BP. Furthermore, he concluded 
that individuals who do not regularly ingest caffeine may 
experience an increase in BP when drinking coffee, but that 
tolerance develops in 2–3 days with BP returning to initial 
levels (Myers 1988). Jee and colleagues (1999) performed a 
meta-analysis of 11 RCT with a median duration of 56 days. 
After pooling of trials, they found a signiﬁ  cant increase in BP 
of 2.4 mmHg systolic and 1.2 mmHg diastolic for a median 
coffee intake of 5 cups per day (Jee et al 1999). Also, they 
reported a dose-response relation between number of cups 
consumed and change in BP, and larger effects in younger 
subjects (Jee et al 1999).
Nurminen and colleagues (1999) performed an extensive 
descriptive review of both epidemiological and experi-
mental studies, from which they concluded that regular 
coffee consumption may be harmful to hypertension-prone 
subjects. In their paper, the authors separated studies with 
continuous ambulatory BP monitoring from studies with Vascular Health and Risk Management 2008:4(5) 967
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BP measurements at the research center. The 10 studies that 
used ambulatory BP were of shorter duration, and half of 
these lasted less than 1 week. Caffeinated coffee (3+ cups 
per day) increased ambulatory BP by around 3–6 mmHg 
in 7 studies, whereas BP was not affected in the remaining 
3 studies (Nurminen et al 1999). In controlled trials that used 
ofﬁ  ce BP, caffeinated coffee caused BP elevation in one-third 
of the studies (Nurminen et al 1999).
Noordzij and colleagues (2005) performed a meta-
analysis of caffeine and coffee trials with a median duration 
of 42 days, excluding studies that lasted 7 days. When 
caffeine trials (n = 7) and coffee trials (n = 18) were analyzed 
separately, BP elevations appeared to be 4 times greater for 
caffeine given as tablets (4.2 mm Hg systolic and 2.4 mm Hg 
diastolic) than for caffeinated coffee (1.2 and 0.5 mm Hg, 
respectively). These differences could not be explained by 
caffeine dose, since the median daily caffeine dose in caf-
feine trials was 400 mg per day (range, 295–750 mg) and 
in coffee trials was 455 mg per day (range, 225–798 mg) 
(Geleijnse 2006). Overall, this study showed a somewhat 
larger systolic BP response to coffee or caffeine in younger 
populations (mean age 40 years), as was also the case in 
the meta-analysis by Jee and colleagues (1999). It should be 
noted that the trials that formed the basis of the abovemen-
tioned meta-analyses were mostly conducted in normotensive 
Caucasian populations that were relatively young (Jee et al 
1999; Noordzij et al 2005). Therefore, the BP estimates from 
these meta-analyses cannot be generalized to other type of 
populations, eg, hypertensives, elderly or Asian subjects, or 
to the population at large.
Recently, a number of new trials related to coffee and BP 
have been published. A Japanese research group repeatedly 
demonstrated a beneﬁ  cial effect of chlorogenic acid from 
green bean coffee extract on vasoreactivity and BP in mild 
hypertensives, with reductions around 3–4 mmHg (Ochiai 
et al 2004; Kozuma et al 2005; Watanabe et al 2006). Another 
Japanese trial showed that coffee (3+ cups per day) reduced 
BP by 7–10 mmHg systolic and 3–7 mmHg diastolic in 
(pre)hypertensive men who consumed 60 ml of alcohol per day 
(Funatsu et al 2005). Sudano and colleagues (2005) showed 
that caffeinated coffee blunted the BP response to mental stress 
in habitual, but not in nonhabitual coffee drinkers, despite pre-
served muscle sympathetic nervous activation. Their ﬁ  ndings 
led to the conclusion that ingredients other than caffeine could 
be responsible for the stimulating effect of coffee on the car-
diovascular system (Sudano et al 2005).
When combining evidence from RCT of coffee and BP, 
it can be concluded that short-term (12 weeks) intake 
of caffeinated coffee, both ﬁ  ltered and instant, causes BP 
elevations around 2/1 mmHg when compared to abstinence 
or use of decaffeinated coffee. BP elevations were more 
apparent when ambulatory BP monitoring was applied 
(Nurminen et al 1999). Stratiﬁ  ed meta-analyses suggest 
larger BP elevations in the case of prolonged coffee use 
(6 weeks), a short run-in period (1 week), younger age 
(40 years) and high levels of coffee intake (5 cups/d) 
(Jee et al 1999; Noordzij et al 2005). However, it should 
be emphasized that there is a lack of trials of coffee and 
BP in elderly, hypertensives and non-Caucasians and no 
conclusions with regard to these subgroups can be drawn. In 
addition, long-term trials of coffee and BP are warranted. As 
a suggestion, habitual noncoffee drinkers may be randomized 
to daily use of pills or capsules that contain ﬁ  ltered coffee 
extract or placebo for a period of 1 year. Preferably, a 2 × 2 
factorial design should be used so that the effect of caffeine 
can be studied separately from other substances in coffee.
Coffee and BP: biological pathways
Most available evidence points toward caffeine as the BP-
raising agent in coffee. Caffeinated and decaffeinated coffee 
were compared in a randomized double-blind, crossover trial 
in 45 habitual coffee drinkers (Van Dusseldorp et al 1989). 
Daily intake of 5 cups of decaffeinated coffee for a period of 
6 weeks signiﬁ  cantly reduced ambulant BP by 1.5 mmHg sys-
tolic and 1.0 mmHg diastolic, compared to a similar amount 
of regular coffee (Van Dusseldorp et al 1989). A number of 
mechanisms have been proposed by which caffeine could 
raise BP, including sympathetic overactivation, antagonism 
of adenosine receptors, increased norepinephrine release via 
direct effects on the adrenal medulla, renal effects, and acti-
vation of the renin–angiotensin system. These mechanisms 
have been discussed in detail by others (Robertson et al 
1978; Myers 1988; Nurminen et al 1999). More recently, a 
Japanese group showed enhanced endothelium-dependent 
vasodilatation after acute caffeine administration in young 
healthy men (Umemura et al 2006), a mechanism by which 
caffeine could lower BP. From experimental research it 
has become clear the caffeine administration acutely raises 
BP, but tolerance to this effect develops rapidly and heavy 
coffee drinkers are less likely to show a BP response after 
caffeine intake (Robertson et al 1981; Ammon et al 1983; 
Myers 1988).
As shown in the meta-analysis by Noordzij and col-
leagues (2005) the BP-raising effect of caffeine when 
ingested through coffee is probably less compared to caf-
feine tablets. One possible explanation could be a difference Vascular Health and Risk Management 2008:4(5) 968
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in bioavailability of caffeine from coffee and tablets. Also, 
coffee is a rich source of bioactive compounds that may 
lower BP (Clarke and Macrae 1985; Schaafsma 1989; Mazur 
et al 1998; Bonita et al 2007; Diaz-Rubio and Saura-Calixto 
2007). The amount of caffeine and other components in 
coffee made in a household coffee-maker with a paper 
ﬁ  lter was quantiﬁ  ed in the Netherlands (Schaafsma 1989). 
It was estimated that 5 cups of coffee per day contribute to 
approximately 26% of the daily intake of potassium, 12% 
of the daily intake of magnesium, 10% of the daily intake of 
manganese, and 15% of the daily intake of niacin (Schaafsma 
1989). Apart from minerals and trace elements, coffee is a 
rich source of polyphenols, including chlorogenic acid and 
the lignan secoisolariciresinol (Mazur et al 1998; Bonita et al 
2007). Recently, it was shown that brewed coffee (espresso, 
ﬁ  lter, instant) contains high amounts of soluble ﬁ  bre and 
associated antioxidant polyphenols (Diaz-Rubio and Saura-
Calixto 2007). It is possible that BP-lowering minerals and 
polyphenols in coffee outweigh potential adverse effects of 
caffeine. This hypothesis was conﬁ  rmed by the prospective 
study in US Nurses (Winkelmayer et al 2005), in which caf-
feinated cola that is poor in polyphenols increased the risk of 
hypertension whereas coffee did not. Also, the meta-analysis 
by Noordzij and colleagues (2005) showed that caffeine 
intake through tablets could be more detrimental to BP than 
caffeine intake through coffee.
In the present review, psychosocial factors related to the 
habit of coffee drinking are not addressed, but it is conceiv-
able that such factors may contribute to either beneﬁ  cial or 
adverse effects on BP. Furthermore, interaction of coffee with 
smoking, alcohol consumption and mental stress may affect 
BP (Myers 1988), but a discussion of mechanisms that could 
underlie such effects is beyond the scope of this review.
In summary, there are many possible biological pathways 
through which a variety of bioactive substances in coffee 
may inﬂ  uence BP, either resulting in an overall BP-lowering 
or a BP-raising effect of coffee. Effects of coffee on BP, if 
any, probably result from activation or inhibition of different 
pathways, and not from caffeine-related pathways only.
Discussion
Epidemiological studies of long-term consumption of ﬁ  ltered 
coffee do not support the hypothesis that ﬁ  ltered caffeinated 
coffee is detrimental to BP. On the contrary, there is observa-
tional evidence that high intake (4 cups per day) may even 
reduce the risk of hypertension, especially in women. The 
nature of the relationship between coffee and BP is not yet 
clear, and further investigation is needed to ﬁ  nd out whether 
abstainers are at a lower or higher risk of hypertension than 
occasional coffee drinkers (1–2 cups per day). Findings from 
experimental studies suggest a BP-raising effect of coffee of a 
few mmHg in the short-term (3 months), but apparently this 
effect does not translate into an increased risk of hypertension 
in the long-term. Both observational and experimental data 
suggest larger BP elevations during coffee intake at younger 
compared to older age (ie, 40 years). However, it should 
be noted that studies on coffee and BP in the elderly are 
sparse, as are studies in several other population subgroups, 
and long-term intervention studies.
A number of methodological issues need further consid-
eration. Firstly, it has been well established that caffeinated 
coffee causes an acute rise in BP shortly after exposure 
(Nurminen et al 1999), as is the case for other lifestyle factors 
such as smoking, alcohol intake, physical activity, and even 
talking. Such acute physiological responses are mostly tran-
sient, with BP returning to initial levels within hours. It is 
not yet clear whether repeated BP elevations during the day 
could eventually lead to persistent hypertension. For coffee, 
on basis of available evidence from prospective studies, this 
does not seem to be the case. In this respect, it should be 
noted that ofﬁ  ce BP measurements both in epidemiological 
and experimental studies are not always performed in fasting 
conditions. From available data, it is hard to judge to what 
extent coffee intake prior to BP assessment (ie, acute BP 
effects) inﬂ  uenced the outcomes of the studies. To illustrate, 
in a trial in young Swiss women, coffee consumption on 
the testing day was associated with elevated BP whereas 
no association was found with habitual intake (Höfer and 
Bättig 1993). Also, ambulatory BP monitoring that captures 
repeated acute BP elevations during coffee intake throughout 
the day may point towards a BP raising effect of coffee, 
while such BP elevations are probably transient. It is recom-
mended that in future studies a sufﬁ  cient time period is incor-
porated between the last cup of coffee and BP assessment, 
to avoid measurement of acute effects. Also, investigators 
should clearly state in their papers the time when the last cup 
of coffee was consumed.
Secondly, it is unclear whether occasional coffee drinkers 
are at higher risk of hypertension than heavy coffee drinkers. 
Also here, acute BP effects may blur the view on the role of 
coffee in the development of hypertension. There is ample 
evidence that habitual coffee users develop tolerance to caf-
feine and show no elevation in BP shortly after intake. BP 
responses will probably not occur in people who take many 
cups of coffee throughout the day (‘continuous infusion’ with 
caffeine). In studies that have no proper time period between Vascular Health and Risk Management 2008:4(5) 969
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BP readings and the last intake of coffee or other caffeinated 
beverages (eg, cup of coffee or tea offered at the research 
center), BP may be temporarily increased in occasional, but 
not in heavy coffee drinkers.
Thirdly, observational epidemiological studies suggest 
that there may be a U-shaped relation between habitual 
coffee intake and BP. Such relation is less clear from RCTs, 
in which effects of coffee on BP are mostly in the posi-
tive direction or absent. This discrepancy may be related 
to the duration of trials compared to cohort studies, and it 
is possible that short-term BP effects are not persistent in 
time. However, other (methodological) aspects may also 
contribute to the discrepancy. Trials generally focus on one 
or two speciﬁ  c doses of coffee, mostly in the high range 
(around 5 cups per day), and there is a lack of experimental 
data on the effect of low intakes on BP. Furthermore, in 
many trials the control treatment comprises cessation of 
coffee use, which from a physiological point of view is truly 
different from non-use in observational studies. ‘Habitual 
abstainers’ do not drink coffee because of disliking, health 
problems (eg, stomach complaints), ﬁ  nancial aspects, or 
other reasons. In addition, observational studies are often 
population-based, whereas trials are conducted in selected 
groups subjects. Finally, coffee consumption in trials is care-
fully monitored whereas observational studies make use of 
self-reported data. The latter could lead to misclassiﬁ  cation 
of subjects. To illustrate, subjects who are aware of having 
high BP may ﬁ  nd it socially desirable to report occasional 
use of coffee rather than higher levels of intake because of a 
general belief that coffee could be harmful to health. Random 
misclassiﬁ  cation of coffee intake, as discussed previously, 
can lead to weakened associations between coffee and BP 
levels or hypertension.
In conclusion, it is at present unclear whether habitual 
coffee drinking is related to risk of hypertension, although 
most evidence suggest that this is not the case. At this 
moment, there is no reason to refrain from coffee for the 
prevention of hypertension. The precise nature of the relation 
between coffee and BP is not yet clear. More prospective 
studies of coffee intake and incident hypertension are needed, 
as are long-term randomized placebo-controlled trials. Future 
studies may focus on different doses of coffee, and on speciﬁ  c 
population subgroups such as the elderly, hypertensives, and 
non-Caucasians. With regard to underlying biological mecha-
nisms, research should not only focus on the BP-raising 
properties of caffeine but also on the potentially beneﬁ  cial 
effect of other substances in coffee, such as polyphenols, 
soluble ﬁ  bre, and potassium.
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